Lupin Limited (LUPIN.NS)
| Previous Close | 1,654.75 |
| Open | 1,667.90 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 1,636.65 - 1,687.00 |
| 52 Week Range | 726.00 - 1,704.25 |
| Volume | |
| Avg. Volume | 1,196,454 |
| Market Cap | 765.732B |
| Beta (5Y Monthly) | 0.65 |
| PE Ratio (TTM) | 42.83 |
| EPS (TTM) | 39.22 |
| Earnings Date | May 07, 2024 |
| Forward Dividend & Yield | 4.00 (0.24%) |
| Ex-Dividend Date | Jul 14, 2023 |
| 1y Target Est | 1,392.03 |
CNW GroupLupin Launches Propranolol Long-Acting Capsules to Improve Heart Health in Canada
Lupin Pharma Canada Ltd., a wholly-owned subsidiary of Lupin Limited (Lupin), today announced the launch of Propranolol LA (long-acting) capsules,60 mg, 80 mg, 120 mg and 160 mg, in Canada. Propranolol LA is a generic equivalent of Inderal® LA, it provides an effective treatment solution since the discontinuation of Inderal® LA for patients and healthcare practitioners. Propranolol LA's launch caters to the needs of Canadian patients,reaffirming Lupin's commitment to enhancing healthcare access
- CNW Group
Lupin Announces Health Canada Approval of Tiotropium Bromide Inhalation Powder for Treatment of COPD
Global pharma major Lupin Limited (Lupin) announced on May 26, 2023, that its Canada subsidiary, Lupin Pharma Canada Ltd., has received approval from Health Canada to market a generic version of Spiriva® (tiotropium bromide inhalation powder) for the treatment of chronic obstructive pulmonary disease (COPD), in Canada. Lupin wishes to clarify that Tiotropium Bromide Inhalation Powder is indicated in Canada for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction i
